Clinical Trial Update: Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor [Phase 3]

View source ↗

Summary

Phase 3 trial comparing two doses of STI571 (imatinib) for metastatic or unresectable gastrointestinal stromal tumor was terminated; the update notes terminatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Gleevec (Imatinib)
• STI571 (imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrointestinal Stromal Tumor | Phase 3 | Status: TERMINATED